AR062585A1 - Derivados de aminopiridina que tienen accion inhibidora sobre aurora a - Google Patents
Derivados de aminopiridina que tienen accion inhibidora sobre aurora aInfo
- Publication number
- AR062585A1 AR062585A1 ARP070103835A ARP070103835A AR062585A1 AR 062585 A1 AR062585 A1 AR 062585A1 AR P070103835 A ARP070103835 A AR P070103835A AR P070103835 A ARP070103835 A AR P070103835A AR 062585 A1 AR062585 A1 AR 062585A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- atom
- group
- lower alkyl
- substituents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
- C07D241/22—Benzenesulfonamido pyrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Un compuesto de formula general (1) en la que R1 es un átomo de H, F, CN, COORa1, CONRa2Ra2', NRa3CORa3', CONRa4ORa4', NRa5CONRa5'Ra5ö, NRa6COORa6', SO2NRa7Ra7', NRa8SO2Ra8', CORa9, SO2Ra10, NO2, ORa11 o NRa12Ra12', en los que: Ra1, Ra3, Ra4, Ra5, Ra6 y Ra8 son cada uno independientemente un átomo de hidrogeno o alquilo inferior; Ra2, Ra2', Ra5', Ra5ö, Ra7, Ra7', Ra12 y Ra12' son cada uno independientemente un átomo de hidrogeno o alquilo inferior que puede estar sustituido con uno o más de los mismos o diferentes sustituyentes seleccionados del grupo <grupo de sustituyentes L1>, en el que <grupo de sustituyentes L1> es un átomo de halogeno, hidroxi, nitro, ciano, amino, carbamoílo, aminosulfonilo, imino, alquilamino inferior, dialquilamino inferior, alquilsulfonilo inferior, alquilsulfonilamino inferior, alcoxi inferior, alcoxicarbonilo inferior, alcoxicarbonilamino inferior, alcanoílo inferior, alcanoiloxi inferior, alquiltio inferior y carboxilo; con tal de, sin embargo, que Ra2 y Ra2'; Ra5' y Ra5ö, Ra7 y Ra7'; Ra12 y Ra12' cada uno independientemente, junto con el átomo de nitrogeno al cual se unen, pueda formar un grupo heterocíclico aromático o alifático de 5 o 6 miembros que puede estar sustituido con uno o más de los mismos o diferentes sustituyentes seleccionados del <grupo de sustituyentes L2>, en el que <grupo de sustituyentes L2> es un átomo de halogeno, hidroxi, amino e hidroximetilo; Ra3', Ra4', Ra6', Ra8', Ra9, Ra10 y Ra11 son cada uno independientemente un átomo de hidrogeno o alquilo inferior que puede estar sustituido con uno o más de los mismos o diferentes sustituyentes seleccionados del grupo <grupo de sustituyentes L1>; o R1 es un alquilo inferior que puede estar sustituido con uno o más de los mismos o diferentes sustituyentes seleccionados de <grupo de sustituyentes M>, en el que <grupo de sustituyentes M> es un átomo de halogeno, hidroxi, nitro, ciano, amino, carbamoílo, aminosulfonilo, imino, alquilamino inferior, dialquilamino inferior, alquilsulfonilo inferior, alquilsulfonilamino inferior, alcoxi inferior, alcoxicarbonilo inferior, alcoxicarbonilamino inferior, alcanoílo inferior, alcanoiloxi inferior, alquiltio inferior y carboxilo; o R1 es un grupo heterocíclico seleccionado de los de formulas (2), en los que Y1 e Y2 son iguales y diferentes, y cada uno es un átomo de hidrogeno o alquilo inferior que puede estar sustituido: R2 es O, S, SO, SO2, NH, NRb, o CRc1Rc2, en los que Rb es alquilo inferior que puede estar sustituido y Rc1 y Rc2, los cuales pueden ser iguales o diferentes, son un átomo de hidrogeno o alquilo inferior; R3 es un fenilo que puede estar sustituido; X2 es CH, CX2a, o N, siendo: X2a un alquilo inferior; o X2a un sustituyente seleccionado de <grupo de sustituyentes A1>, o alquilo inferior que está sustituido con uno o más de los mismos o diferentes sustituyentes seleccionados de <grupo de sustituyentes A1>, en el que <grupo de sustituyentes A1> es un átomo de halogeno; ciano; hidroxi; alquilamino inferior; dialquilamino inferior; alcoxi inferior que puede estar sustituido con uno o más grupos hidroxi; alquiltio inferior; y alquilsulfonilo inferior; o X2a es COORx1, CONRx2Rx3, NHCOx1, NHCONRx2Rx3, NHSO2NRx2Rx3, NRx4Rx5, o CH2NRx4Rx5, en los que: Rx1 es un átomo de hidrogeno o alquilo inferior que puede estar sustituido; Rx2 y Rx3, los cuales pueden ser iguales o diferentes, son cada uno un átomo de hidrogeno, alquilo inferior que puede estar sustituido o cicloalquilo que puede estar sustituido; o de forma alternativa Rx2 y Rx3, junto con el átomo de nitrogeno al cual se unen, pueden formar un grupo heterocíclico aromático o alifático de 5 o 6 miembros que contenga al menos un átomo seleccionado de N, O y S y que pueda estar sustituido; y Rx4 y Rx5, los cuales pueden ser iguales o diferentes, son cada uno un átomo de hidrogeno, alquilo inferior que puede estar sustituido o cicloalquilo que puede estar sustituido; o X2a es un grupo heterocíclico alifático de 5 o 6 miembros que contiene al menos un átomo seleccionado de N, O y S y que pueda estar sustituido, en el que dos átomos de hidrogeno que están unidos al mismo átomo de carbono del grupo heterocíclico alifático pueden estar sustituidos con oxo y la proximidad de dos átomos de carbono que constituyen el anillo heterocíclico alifático puede formar un doble enlace; o alquilo inferior que está sustituido con el grupo heterocíclico alifático; o X2a es un grupo heterocíclico alifático de 5 o 6 miembros que contiene al menos un átomo seleccionado de N, O y S y que pueda estar sustituido; o alquilo inferior que está sustituido con el grupo heterocíclico aromático; X es el resto e formula (3) en el que W1 es CH, N, NH, O o S; W2 es CH, CW2a, N, NW2b, O o S, en los que W2a y W2b son cada uno independientemente un átomo de hidrogeno, un átomo de halogeno, ciano, alquilo inferior que tiene uno o dos átomos de carbono, cicloalquilo que tiene tres a cinco átomos de carbono o alquilo inferior que tiene uno a dos átomos de carbono que pueden estar sustituidos con uno o más átomos de halogeno; W3 es C o N; y al menos uno de W1, W2 y W3 es un átomo de carbono; sin embargo, dos de W1 W2 y W3 no son simultáneamente O y S, o una de sus sales o ésteres farmacéuticamente aceptables.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006236472 | 2006-08-31 | ||
| US92608607P | 2007-04-25 | 2007-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062585A1 true AR062585A1 (es) | 2008-11-19 |
Family
ID=39136042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103835A AR062585A1 (es) | 2006-08-31 | 2007-08-29 | Derivados de aminopiridina que tienen accion inhibidora sobre aurora a |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20100016335A1 (es) |
| EP (2) | EP2062887B1 (es) |
| JP (3) | JP2008081492A (es) |
| KR (1) | KR20090055562A (es) |
| CN (1) | CN101528731B (es) |
| AR (1) | AR062585A1 (es) |
| AU (1) | AU2007289609B2 (es) |
| CA (1) | CA2657469C (es) |
| CL (1) | CL2007002519A1 (es) |
| CO (1) | CO6190529A2 (es) |
| CR (1) | CR10553A (es) |
| EC (1) | ECSP099062A (es) |
| ES (1) | ES2389515T3 (es) |
| GT (1) | GT200900008A (es) |
| HN (1) | HN2009000113A (es) |
| IL (1) | IL196497A0 (es) |
| MA (1) | MA30719B1 (es) |
| MX (1) | MX2009000390A (es) |
| NO (1) | NO20091301L (es) |
| NZ (1) | NZ574081A (es) |
| PE (1) | PE20080835A1 (es) |
| RU (1) | RU2437880C2 (es) |
| SV (1) | SV2009003152A (es) |
| TW (1) | TW200817363A (es) |
| UA (1) | UA95972C2 (es) |
| WO (2) | WO2008026769A1 (es) |
| ZA (1) | ZA200900126B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2531398T3 (es) * | 2008-02-22 | 2015-03-13 | Msd Kk | Nuevos derivados de aminopiridina que tienen una acción inhibidora selectiva de Aurora A |
| AU2009233315B2 (en) * | 2008-03-31 | 2013-08-29 | Sun Pharmaceutical Industries Ltd. | An improved process for the preparation of morphinane analogues |
| WO2010009985A2 (en) * | 2008-07-24 | 2010-01-28 | Nerviano Medical Sciences S.R.L. | Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents |
| US9567318B2 (en) | 2009-08-17 | 2017-02-14 | Memorial Sloan-Kettering Cancer Center | Substituted pyrimidine compounds and uses thereof |
| JP5878178B2 (ja) | 2011-09-30 | 2016-03-08 | 大鵬薬品工業株式会社 | １，２，４−トリアジン−６−カルボキサミド誘導体 |
| TWI485146B (zh) * | 2012-02-29 | 2015-05-21 | Taiho Pharmaceutical Co Ltd | Novel piperidine compounds or salts thereof |
| US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
| KR102461419B1 (ko) | 2014-05-13 | 2022-11-02 | 메모리얼 슬로안 케터링 캔서 센터 | Hsp70 조정물질 및 이의 제조 및 이용 방법 |
| TWI693218B (zh) * | 2014-11-14 | 2020-05-11 | 美商美國禮來大藥廠 | 極光ａ激酶抑制劑 |
| US10866838B2 (en) * | 2015-03-25 | 2020-12-15 | Intel Corporation | Cluster computing service assurance apparatus and method |
| CN108250191B (zh) * | 2018-03-15 | 2020-10-20 | 兰州大学 | 一种3,5-二取代的2-氨基-吡嗪化合物及其制备工艺与应用 |
| WO2020049208A1 (es) | 2018-09-09 | 2020-03-12 | Fundacio Privada Institut De Recerca De La Sida - Caixa | Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida |
| CN112898292A (zh) * | 2019-12-03 | 2021-06-04 | 微境生物医药科技(上海)有限公司 | 新型极光激酶抑制剂及其用途 |
| TWI785474B (zh) | 2020-01-22 | 2022-12-01 | 大陸商北京加科思新藥研發有限公司 | 用作選擇性Aurora A抑制劑的新型雜環化合物 |
| WO2023196887A1 (en) | 2022-04-08 | 2023-10-12 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and aurora a inhibitors |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| OA07174A (fr) | 1981-08-24 | 1984-04-30 | May & Baker Ltd | Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent. |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5223608A (en) | 1987-08-28 | 1993-06-29 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
| DK0547165T3 (da) | 1990-09-28 | 2000-03-27 | Smithkline Beecham Corp | Fremgangsmåde til fremstilling af vandopløselige camptothecinanaloger såvel som forbindelserne 10-hydroxy-11-C(1-6)-alkoxyc |
| US5200524A (en) | 1990-12-20 | 1993-04-06 | North Carolina State University | Camptothecin intermediates and method of making same |
| US5191082A (en) | 1990-12-20 | 1993-03-02 | North Carolina State University | Camptothecin intermediate and method of making camptothecin intermediates |
| US5247089A (en) | 1990-12-20 | 1993-09-21 | North Carolina State University | Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs |
| US5243050A (en) | 1990-12-20 | 1993-09-07 | North Carolina State University | Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs |
| US5162532A (en) | 1990-12-20 | 1992-11-10 | North Carolina State University | Intermediates and method of making camptothecin and camptothecin analogs |
| HU221343B1 (en) | 1992-10-28 | 2002-09-28 | Genentech Inc | Use of anti-vegf antibodies for the treatment of cancer |
| JP3025602B2 (ja) | 1993-05-21 | 2000-03-27 | デビオファーム エス．アー． | 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法 |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| EP0831880A4 (en) | 1995-06-07 | 2004-12-01 | Imclone Systems Inc | ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH |
| JP3154399B2 (ja) | 1996-07-04 | 2001-04-09 | デビオファーム エス．アー． | 白金化合物の製造方法 |
| PE92198A1 (es) | 1996-08-01 | 1999-01-09 | Banyu Pharma Co Ltd | Derivados de 1,4-piperidina disustituida que contienen fluor |
| SK4772002A3 (en) | 1999-09-10 | 2002-11-06 | Merck & Co Inc | Tyrosine kinase inhibitors, pharmaceutical composition containing the same and their use |
| AU2002213467A1 (en) | 2000-10-11 | 2002-04-22 | Chemocentryx, Inc. | Modulation of ccr4 function |
| US20020137755A1 (en) | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
| ES2265452T3 (es) * | 2000-12-21 | 2007-02-16 | Vertex Pharmaceuticals Incorporated | Compuestos de pirazol utiles como inhibidores de la proteina quinasa. |
| WO2002094264A1 (en) | 2001-05-23 | 2002-11-28 | Tularik Inc. | Ccr4 antagonists |
| US7709475B2 (en) * | 2004-05-21 | 2010-05-04 | Banyu Pharmaceutical Co., Ltd. | Selective inhibitors against Cdk4 and Cdk6 having aminothiazole skeleton |
| JP4973190B2 (ja) * | 2004-10-29 | 2012-07-11 | Ｍｓｄ株式会社 | オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体 |
| US7491720B2 (en) * | 2004-10-29 | 2009-02-17 | Banyu Pharmaceutical Co., Ltd. | Aminopyridine derivatives having Aurora A selective inhibitory action |
| TW200628463A (en) | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | Heteroaryl compounds |
| GB0428082D0 (en) | 2004-12-22 | 2005-01-26 | Welcome Trust The Ltd | Therapeutic compounds |
| JP2008526777A (ja) | 2005-01-05 | 2008-07-24 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ユビキチンリガーゼインヒビター |
| US7928126B2 (en) * | 2005-04-28 | 2011-04-19 | Mitsubishi Tanabe Pharma Corporation | Cyanopyridine derivative and use thereof as medicine |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| WO2006129842A1 (ja) * | 2005-06-01 | 2006-12-07 | Banyu Pharmaceutical Co., Ltd. | オーロラa選択的阻害作用を有する新規アミノピリジン誘導体 |
| US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
-
2007
- 2007-04-26 JP JP2007116649A patent/JP2008081492A/ja not_active Withdrawn
- 2007-08-29 NZ NZ574081A patent/NZ574081A/en not_active IP Right Cessation
- 2007-08-29 CA CA2657469A patent/CA2657469C/en not_active Expired - Fee Related
- 2007-08-29 US US12/310,307 patent/US20100016335A1/en not_active Abandoned
- 2007-08-29 CL CL200702519A patent/CL2007002519A1/es unknown
- 2007-08-29 RU RU2009111599/04A patent/RU2437880C2/ru not_active IP Right Cessation
- 2007-08-29 UA UAA200902851A patent/UA95972C2/ru unknown
- 2007-08-29 TW TW096132117A patent/TW200817363A/zh unknown
- 2007-08-29 US US11/897,272 patent/US7915263B2/en active Active
- 2007-08-29 EP EP07806706A patent/EP2062887B1/en active Active
- 2007-08-29 AU AU2007289609A patent/AU2007289609B2/en not_active Ceased
- 2007-08-29 EP EP07806705A patent/EP2061782A4/en not_active Withdrawn
- 2007-08-29 WO PCT/JP2007/067251 patent/WO2008026769A1/ja active Application Filing
- 2007-08-29 MX MX2009000390A patent/MX2009000390A/es active IP Right Grant
- 2007-08-29 JP JP2008532150A patent/JP4466782B2/ja active Active
- 2007-08-29 WO PCT/JP2007/067250 patent/WO2008026768A1/en active Application Filing
- 2007-08-29 CN CN200780032242.7A patent/CN101528731B/zh not_active Expired - Fee Related
- 2007-08-29 ES ES07806706T patent/ES2389515T3/es active Active
- 2007-08-29 PE PE2007001171A patent/PE20080835A1/es not_active Application Discontinuation
- 2007-08-29 AR ARP070103835A patent/AR062585A1/es unknown
- 2007-08-29 KR KR1020097004339A patent/KR20090055562A/ko not_active Application Discontinuation
-
2009
- 2009-01-07 ZA ZA200900126A patent/ZA200900126B/xx unknown
- 2009-01-13 CR CR10553A patent/CR10553A/es not_active Application Discontinuation
- 2009-01-13 IL IL196497A patent/IL196497A0/en unknown
- 2009-01-13 EC EC2009009062A patent/ECSP099062A/es unknown
- 2009-01-13 HN HN2009000113A patent/HN2009000113A/es unknown
- 2009-01-13 GT GT200900008A patent/GT200900008A/es unknown
- 2009-01-14 SV SV2009003152A patent/SV2009003152A/es unknown
- 2009-01-14 CO CO09002429A patent/CO6190529A2/es not_active Application Discontinuation
- 2009-03-20 MA MA31731A patent/MA30719B1/fr unknown
- 2009-03-30 NO NO20091301A patent/NO20091301L/no not_active Application Discontinuation
- 2009-10-29 JP JP2009248400A patent/JP5256168B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062585A1 (es) | Derivados de aminopiridina que tienen accion inhibidora sobre aurora a | |
| ES2531398T3 (es) | Nuevos derivados de aminopiridina que tienen una acción inhibidora selectiva de Aurora A | |
| ES2579855T3 (es) | Compuestos de imidazopiridinil-aminopiridina sustituidos | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| AR108356A1 (es) | Derivados aromáticos de sulfonamida | |
| AR067674A1 (es) | Derivados de pirazol utiles para el tratamiento con un antagonista de receptor ccr2 | |
| CO6190609A2 (es) | Compuestos de urea policiclicos antibacterianos | |
| CO6210721A2 (es) | Acilaminopirazoles como inhibidores de fgfr | |
| AR066169A1 (es) | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat | |
| CO5680435A2 (es) | Derivados de quinazolina inhibidores de tirosina quinasa erbb y egb, su procedimiento de sintesis y composiciones farmaceuticas que los contienen | |
| AR058198A1 (es) | Derivados de morfolina y composiciones farmaceuticas | |
| AR054814A1 (es) | Derivados de piridazina | |
| AR067327A1 (es) | Derivados de piperidina / piperazina | |
| AR051342A1 (es) | Derivados de purina, purinona, deazapurina y deazapurinona como inhibidores de la actividad de la protein quinasa; metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de un medicamento para el tratamiento de enfermedades mediadas por la protein quina | |
| AR066153A1 (es) | Derivados de piperidina / piperazina | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| AR041250A1 (es) | Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa | |
| UY31711A (es) | Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización | |
| AR041734A1 (es) | Compuestos de alquino con efecto antagonico de la hcm y medicamentos que contienen estos compuestos | |
| AR047537A1 (es) | Piridazinonaureas como antagonistas de integrinas | |
| AR086411A1 (es) | Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria | |
| AR072281A1 (es) | Isoquinolinas e isoquinolinonas sustituidas | |
| AR076401A1 (es) | Bisaril alquinilamidas como moduladores alostericos negativos del receptor metabotropico de glutamato 5 (mglur5) | |
| AR066154A1 (es) | Derivados de piperidina / piperazina | |
| AR068627A1 (es) | Inhibidores de la interaccion entre mdm2 y p53 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |